IDH1 and astrocytoma (excluding glioblastoma): The IDH1/2 inhibitor vorasidenib was recently shown in a double-blind, placebo-controlled phase 3 clinical trial to prolong PFS (27.7 months vs. 11.1 months) and time-to-next intervention in patients with IDH-mutant grade II astrocytomas and oligoendrogliomas [17].